MedTrace Logo

A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis

NCT04439526 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 356

Last updated 2024-01-05

No results posted yet for this study

Summary

The purpose of this study is to investigate the effectiveness profile of guselkumab used in a real-life setting in participants with moderate facial and/or genital psoriasis. Effectiveness will be evaluated using the static Physicians Global Assessment (sPGA) for the facial region and the sPGA for the genital region.

Conditions

Interventions

DRUG

Guselkumab

Participants with moderate facial and/or genital psoriasis treated with guselkumab (as prescribed by their physician) in real world practice will be observed in this study.

Sponsors & Collaborators

  • Janssen-Cilag S.p.A.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag S.p.A., Italy Clinical Trial · Janssen-Cilag S.p.A.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-10
Primary Completion
2023-11-21
Completion
2023-11-21

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04439526 on ClinicalTrials.gov